<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0">
	<channel>
	<link>http://salesandmarketingnetwork.com/reports_summary.php</link>
	<title>Healthcare Sales &amp; Marketing Network: Market Research Marketplace</title>
	<description><![CDATA[Authoritative, up-to-the-minute reports and analysis of the medical device and biopharmaceutical market sectors]]></description>
	<lastBuildDate>Thu, 11 Mar 2010 08:53:41 CST</lastBuildDate>
	<language>en-us</language>
	<image>
	<title><![CDATA[The Healthcare Sales & Marketing Network]]></title>
	<width>150</width>
	<height>67</height>
	<link>http://salesandmarketingnetwork.com/reports_summary.php</link>
	<url>http://salesandmarketingnetwork.com/images/hsmn_logo_150.gif</url>
	</image>
	<item>
		 <title><![CDATA[The Top 10 Generic Pharmaceutical Companies: Positioning, performance and SWOT analyses]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2670</link>
			<author><![CDATA[Source: Business Insights]]></author>
		 <description><![CDATA[The Top 10 Generic Pharmaceutical Companies
Positioning, performance and SWOT analyses

The global generics market grew at a faster pace than the global pharma market in 2007, with a CAGR of 16.4% during 2004–2007. Regular patent expirations of blockbus... <br/><font color="red">Category:   Special price offers!</font><br/><font color="blue">Published: Jul-08</font><br/><font color="teal">Pages: 178</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[The Promotional Landscape in US and Europe: Benchmarking promotional ROI and optimizing detailing and journal spend]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2767</link>
			<author><![CDATA[Source: Business Insights]]></author>
		 <description><![CDATA[The Promotional Landscape in the US and Europe
Benchmarking promotional ROI and optimizing detailing and journal spend relationships

Promotional activities within the pharma industry operate through various sales and promotional channels with the aim o... <br/><font color="red">Category:   Special price offers!</font><br/><font color="blue">Published: Nov-08</font><br/><font color="teal">Pages: 102</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Commercial Insight: Targeted Therapy Cancer Brands - High growth market will see eight new blockbusters by 2017]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2678</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Targeted therapies are the top selling class of cancer drug, reaching sales of nearly $15 billion in the seven major pharmaceutical markets in 2007. The high growth of this therapy class makes it attractive to drug developers, resulting in ... <br/><font color="red">Category:   Special price offers!</font><br/><font color="blue">Published: 18-Jul-08</font><br/><font color="teal">Pages: 272</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Generic Series: Optimizing Brand Lifecycle Management  Winning Strategies to Maximize Revenue in the Face of Growing Generic Competition]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2683</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

As competitive pressures from the entry of generics post-patent expiry and new brands are growing, product lifecycles are evolving for the worst. Effective lifecycle management is becoming a must for Pharma looking to maximize their return ... <br/><font color="red">Category:   Special price offers!</font><br/><font color="blue">Published: 15-Jul-08</font><br/><font color="teal">Pages: 148</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Big Pharma M&A Analysis to 2012 -  Surveying the growth rate landscape]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2744</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

With sales growth rates expected to fall below their historic levels, Big Pharma must act to bolster its performance out to 2012 if it is to maintain the investment community's valuation of its stocks. One mechanism for plugging the sales g... <br/><font color="red">Category:   Special price offers!</font><br/><font color="blue">Published: 21-Aug-08</font><br/><font color="teal">Pages: 244</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Stakeholder Opinions: Vaccine adjuvants - uncertainties rule]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2738</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Adjuvants are coming increasingly into focus for vaccine developers since many novel split- and subunit vaccines are insufficiently immunogenic on their own. Adjuvants offer a solution: they can accelerate, enhance and prolong the immune re... <br/><font color="red">Category:   Special price offers!</font><br/><font color="blue">Published: 12-Sep-08</font><br/><font color="teal">Pages: 147</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Sales Force Effectiveness]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2762</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

The traditional sales force model is no longer effective as doctors are no longer the key prescribing decision makers. Governments and payers are implementing cost cutting initiatives and promoting generic use in an attempt to control escal... <br/><font color="red">Category:   Special price offers!</font><br/><font color="blue">Published: 9/29/2008</font><br/><font color="teal">Pages: 91</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[eHealthInsight Series: The Changing Direct-to-Consumer Advertising Landscape]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2818</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

An effective DTC strategy can catapult a drug into blockbuster status. However, after a 10 year period of skyrocketing DTC budgets, Pharma is now opting for lower cost and more targeted approaches. Pharma faces tighter DTC regulations in th... <br/><font color="red">Category:   Special price offers!</font><br/><font color="blue">Published: 9-Dec-08</font><br/><font color="teal">Pages: 95</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Generics Series: Generics Trends in the Seven Major Markets and Beyond]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2816</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Based on generics use, the seven major markets may be divided into mature (the US, Germany and the UK) and immature (France, Italy, Spain and Japan) markets, both of which present different challenges, making the fast-growing, high-value em... <br/><font color="red">Category:   Special price offers!</font><br/><font color="blue">Published: 11-Dec-08</font><br/><font color="teal">Pages: 107</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Altus Pharmaceuticals: Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2453</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Altus is focused on developing and commercializing protein therapeutics for gastrointestinal and metabolic disorders. The company's product candidates are based on its proprietary protein crystallization technology. Altus's two lead product... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 25-Oct-07</font><br/><font color="teal">Pages: 52</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Alexza Pharmaceuticals: Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2501</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Alexza was founded in 2000 as FaxMed and changed its name to Alexza Corporation in June 2001 and to Alexza Molecular Delivery Corporation in December 2001. Further, it changed its name to its present one Alexza Pharmaceuticals in July 2005.... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 13-Feb-08</font><br/><font color="teal">Pages: 47</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Alexion Pharmaceuticals: Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2500</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Alexion Pharmaceuticals (Alexion) is a biotechnology company engaged in the discovery and development of therapeutic products for the treatment of hematological diseases, cancer, and autoimmune disorders. The company started marketing Solir... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 13-Feb-08</font><br/><font color="teal">Pages: 52</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Achillion Pharmaceuticals: Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2440</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Achillion is developing treatments for HIV infection, chronic hepatitis C infection and serious hospital-based bacterial infections. The company has advanced its lead drug candidate, Elvucitabine for the treatment of HIV infection, into Pha... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 01-Nov-07</font><br/><font color="teal">Pages: 44</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Biosimilars Series: Strategic issues - Potential remains uncertain]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2362</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Significant barriers to entry into the biosimilars market exist. High up-front investment and the need for specific expertise favor big players. Understanding of the marketplace is critical for success acceptance by key stakeholders is cruc... <br/><font color="red">Category: Biosimilars</font><br/><font color="blue">Published: 3-Oct-07</font><br/><font color="teal">Pages: 104</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Biosimilars Series: Regulatory and development issues  hurdles exist but are surmountable]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2332</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Europe serves as a model for other countries looking to define their own regulatory approval criteria. The US is on the brink of passing legislation to establish a statutory pathway for biosimilars approval but the opposing interests of bio... <br/><font color="red">Category: Biosimilars</font><br/><font color="blue">Published: 13-Sep-07</font><br/><font color="teal">Pages: 135</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Biosimilars: Benchmarking the key players - With increasing regulatory clarity and high revenue potential, interest in biosimilars increases]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=1556</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

With increasing regulatory clarity and the expiries of key patents covering innovator biologics, the development of biosimilars for a range of recombinant protein classes is becoming increasingly attractive. Although many companies are targ... <br/><font color="red">Category: Biosimilars</font><br/><font color="blue">Published: 20-Dec-06</font><br/><font color="teal">Pages: 109</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[sanofi-aventis: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2817</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for Sanofi-Aventis in the pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 10-Dec-08</font><br/><font color="teal">Pages: 162</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Actelion Ltd: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2815</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for Actelion in the Rx  pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 11-Dec-08</font><br/><font color="teal">Pages: 126</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Sandoz: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2808</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for Sandoz in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, w... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 18-Dec-08</font><br/><font color="teal">Pages: 122</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[H. Lundbeck: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2807</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for Lundbeck in the prescription pharma global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key d... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 18-Dec-08</font><br/><font color="teal">Pages: 86</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Gilead Sciences: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2806</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for Gilead in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, w... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 18-Dec-08</font><br/><font color="teal">Pages: 104</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Novartis AG: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2802</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for Novartis in the prescription pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 19-Dec-08</font><br/><font color="teal">Pages: 159</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Cephalon: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2791</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for Cephalon in the prescription pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 23-Dec-08</font><br/><font color="teal">Pages: 113</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Allergan: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2788</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for Allergan in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 ... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 25-Dec-08</font><br/><font color="teal">Pages: 86</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Barr Pharmaceuticals Inc.: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2787</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for Barr in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, wit... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 25-Dec-08</font><br/><font color="teal">Pages: 109</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Sepracor: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2785</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for Sepracor in the prescription pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 27-Oct-08</font><br/><font color="teal">Pages: 111</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Menarini: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2782</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for Menarini in the prescription pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 6-Nov-08</font><br/><font color="teal">Pages: 95</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[King Pharmaceuticals: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2774</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for King in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, wit... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 24-Nov-08</font><br/><font color="teal">Pages: 135</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Forest Laboratories: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2773</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for Forest in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, w... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 24-Nov-08</font><br/><font color="teal">Pages: 99</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Merck & Co: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2772</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for Merck & Co. in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 24-Nov-08</font><br/><font color="teal">Pages: 170</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Allos Therapeutics: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2569</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Allos Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of cancer. The company’s lead product candidate, PDX, is currently in Phase II/I for various cancers. This... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 45</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Watson Pharmaceuticals Inc.: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2789</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for Watson in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis with 1-6 year sales forecasts for key drug... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 23-Dec-08</font><br/><font color="teal">Pages: 118</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Teva Pharmaceutical Industries Ltd: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2786</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for Teva in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, wit... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 25-Dec-08</font><br/><font color="teal">Pages: 59</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Shire plc: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2781</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for Shire in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 10-Nov-08</font><br/><font color="teal">Pages: 158</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Mylan: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2790</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for Mylan in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, wi... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 23-Dec-08</font><br/><font color="teal">Pages: 125</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Biotech Financing in the Credit Crisis: Strategies for a radically altered landscape]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2801</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Since the financial meltdown, the relationship between Pharma and Biotech has been turned on its head. Previously, pharma companies had no choice but to license Biotech drugs at high prices in order to fill their sparse late stage pipelines.
... <br/><font color="red">Category:  Editor's Choice Reports</font><br/><font color="blue">Published: 22-Dec-08</font><br/><font color="teal">Pages: 93</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Biotechnology: Global Industry Guide]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2769</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Datamonitor's Biotechnology: Global Industry Guide is an essential resource for top-level data and analysis covering the biotechnology industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive l... <br/><font color="red">Category:  Editor's Choice Reports</font><br/><font color="blue">Published: 30-Nov-08</font><br/><font color="teal">Pages: 207</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Commercial Insight: Community Antibacterials - Pipelines wither as generic tidal wave takes its toll]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2792</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Datamonitor research points to this sector, beleaguered by patent expiries, barriers to market entry and uptake, becoming increasingly inclement towards branded drugs. Generic incursion has taken a heavy toll on the market at a number of leve... <br/><font color="red">Category:  Editor's Choice Reports</font><br/><font color="blue">Published: 8-Jan-09</font><br/><font color="teal">Pages: 212</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Commercial Insight: Rheumatoid arthritis - Anti-TNFs defend first-line biologic position despite competition]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2799</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Datamonitor forecasts that total sales for the seven major rheumatoid arthritis markets will grow from $7 billion in 2007 to over $12 billion in 2017. The sustained uptake of anti-TNFs combined with the launch of several new biologic products... <br/><font color="red">Category:  Editor's Choice Reports</font><br/><font color="blue">Published: 23-Dec-08</font><br/><font color="teal">Pages: 272</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Commercial Insight: Solid organ transplantation - The impact of new biologics, generics and reformulations]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2810</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

The transplant immunosuppressant market has seen considerable growth in recent years, but this is expected to slow down. Two factors combine to cause a decline in the market from 2011, the limited availability of donor organs and patent expir... <br/><font color="red">Category:  Editor's Choice Reports</font><br/><font color="blue">Published: 18-Dec-08</font><br/><font color="teal">Pages: 214</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Divestment Strategies: Pharma is divesting in order to grow]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2795</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Pharmaceutical companies are now divesting non-core assets such as medical devices and manufacturing plants in an effort to cut costs and focus on core strategies, primarily drug development. However, while some Pharma companies are narrowing... <br/><font color="red">Category:  Editor's Choice Reports</font><br/><font color="blue">Published: 25-Dec-08</font><br/><font color="teal">Pages: 68</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Forecast Insight: Antithrombotics - Market growth dependent on new agents]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2796</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

The antithrombotic market is expected to grow to $22 billion by 2017. The growth will mainly be due to the introduction of new agents onto the market, such as prasugrel and rivaroxaban, which will offer significant improvements over the curre... <br/><font color="red">Category:  Editor's Choice Reports</font><br/><font color="blue">Published: 25-Dec-08</font><br/><font color="teal">Pages: 73</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Forecast Insight: Depression - Generic induced brand erosion leads to market decline]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2804</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

The depression market was valued at around $11.04 billion in 2007 across the seven major markets. Following marginal growth to 2011 ($12.01 billion), the market is forecast to decline in value through to 2017 ($9.81 billion) when brand erosio... <br/><font color="red">Category:  Editor's Choice Reports</font><br/><font color="blue">Published: 19-Dec-08</font><br/><font color="teal">Pages: 90</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Forecast Insight: Epilepsy - Future market upgrade following new drug launches]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2798</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Driven primarily by continued uptake of UCB's market leading anticonvulsant, Keppra (levetiracetam), seven major market epilepsy revenues grew strongly at a compound annual growth rate of 11.7% to reach almost $3.8 billion in 2007.

Scope

*T... <br/><font color="red">Category:  Editor's Choice Reports</font><br/><font color="blue">Published: 23-Dec-08</font><br/><font color="teal">Pages: 140</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Forecast Insight: Migraine - Generic incursion inhibits market growth]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2814</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Led by the seven triptan brands and Topamax's (topiramate; Johnson & Johnson) continued uptake, seven major market migraine revenues grew strongly at an annual rate of 12.6% to total $4.1 billion in 2007.

Scope

*This report gives a strategi... <br/><font color="red">Category:  Editor's Choice Reports</font><br/><font color="blue">Published: 17-Dec-08</font><br/><font color="teal">Pages: 80</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Generics: Global Industry Guide]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2768</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Datamonitor's Generics: Global Industry Guide is an essential resource for top-level data and analysis covering the generics industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, ... <br/><font color="red">Category:  Editor's Choice Reports</font><br/><font color="blue">Published: 30-Nov-08</font><br/><font color="teal">Pages: 197</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Infectious Diseases Vaccine Market Overview: Key Companies & Strategies - In times of crisis, Big Pharma turns to vaccines]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2809</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Long being regarded as an unattractive market, vaccines have re-emerged as successful growth driver for Big Pharma. The launch and rapid uptake of novel, high-price products such as Wyeth's Prevnar or Merck & Co's Gardasil, along with the eme... <br/><font color="red">Category:  Editor's Choice Reports</font><br/><font color="blue">Published: 18-Dec-08</font><br/><font color="teal">Pages: 267</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Intellectual Property and Outsourcing in China: Minimizing risk whilst maximizing return on investment]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2763</link>
			<author><![CDATA[Source: Business Insights]]></author>
		 <description><![CDATA[Intellectual Property and Outsourcing in China: Minimizing risk whilst maximizing return on investment

 

The pharma outsourcing industry in China has experienced over 35% year on year growth in the past few years. Increasingly, the sophisticated service ... <br/><font color="red">Category:  Editor's Choice Reports</font><br/><font color="blue">Published: Dec-08</font><br/><font color="teal">Pages: 128</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Molecular Diagnostics: a primer on an emerging sector]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2776</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This report analyzes the emerging sector of molecular diagnostics. It provides a clear classification, assessing the leading technologies and key tests which are positioned in this exciting area of diagnostics. The current MDx market size and... <br/><font color="red">Category:  Editor's Choice Reports</font><br/><font color="blue">Published: 19-Nov-08</font><br/><font color="teal">Pages: 147</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Orthopedics: Global Industry Guide]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2770</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Datamonitor's Orthopedics: Global Industry Guide is an essential resource for top-level data and analysis covering the orthopedics industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive lands... <br/><font color="red">Category:  Editor's Choice Reports</font><br/><font color="blue">Published: 30-Nov-08</font><br/><font color="teal">Pages: 131</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Pharmaceutical Company Outlook to 2013]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2793</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

PharmaVitae universe Rx sales are forecast to expand at a 2007-13 CAGR of 2.4%, down 7.6 percentage points from 2001-07. The underlying cause of this falling rate is the much-discussed genericization of small molecule products. However, not a... <br/><font color="red">Category:  Editor's Choice Reports</font><br/><font color="blue">Published: 26-Dec-08</font><br/><font color="teal">Pages: 137</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Pipeline and Commercial Insight: Anxiety Disorders - Viable indication for antipsychotics companies]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2777</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Despite forming the mainstay of pharmacological treatment of anxiety disorders, response rates to serotonergic-based treatments are often less than robust. As such, physicians are increasingly looking towards novel drugs. For pharmaceutical c... <br/><font color="red">Category:  Editor's Choice Reports</font><br/><font color="blue">Published: 19-Nov-08</font><br/><font color="teal">Pages: 257</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Pipeline and Commercial Insight: Hepatitis C - High unmet need drives rapid innovation]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2812</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

The Hepatitis C market was worth $2.3 billion in 2007, declining at a CAGR of -2.8% from 2004-2007. Despite this recent slump, Datamonitor forecasts sales to grow to $4.5 billion by 2017, driven primarily by the launch of the new protease inh... <br/><font color="red">Category:  Editor's Choice Reports</font><br/><font color="blue">Published: 18-Dec-08</font><br/><font color="teal">Pages: 177</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Pipeline Insight: Cancer Overview - Gastrointestinal, Skin, Sarcomas]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2803</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

In 2008, the six tumor types covered in this report are forecast to account for over 961,000 new cases of cancer. Collectively, the 32 different drugs in Phase III development for the six tumor types are forecast to achieve $4,789m in sales b... <br/><font color="red">Category:  Editor's Choice Reports</font><br/><font color="blue">Published: 19-Dec-08</font><br/><font color="teal">Pages: 265</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Pipeline Insight: Molecular Targeted Cancer Therapies - More pipeline activity, less product differentiation]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2771</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Approaches to cancer treatment continue to incorporate molecular targeted therapies into standard treatment regimens. With an increasing number of candidates gaining approval, and with a dynamic developmental pipeline, further clinical, comme... <br/><font color="red">Category:  Editor's Choice Reports</font><br/><font color="blue">Published: 25-Nov-08</font><br/><font color="teal">Pages: 431</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Pipeline Insight: Orphan Diseases in Neurology - Part III: Myasthenia Gravis]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2784</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

The myasthenia gravis market is set to grow from $44m in 2007 to $239m in 2017 across the seven major pharmaceutical markets in Datamonitor's base scenario forecast. Amarin's pipeline candidate EN101 is forecast to become the market leading b... <br/><font color="red">Category:  Editor's Choice Reports</font><br/><font color="blue">Published: 5-Nov-08</font><br/><font color="teal">Pages: 108</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Stakeholder Insight: Acute Coronary Syndromes  ACS in Europe, what is the best practice?]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2794</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

The face of ACS continues to change. The ageing population and pressure of growing risk factors have made a significant impact on the management strategies in ACS. This report extends the previous year report and unveils the true picture thro... <br/><font color="red">Category:  Editor's Choice Reports</font><br/><font color="blue">Published: 25-Dec-08</font><br/><font color="teal">Pages: 162</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Stakeholder Insight: Chronic Leukemias - Is there room left for improvement?]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2775</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

CLL is the most common form of leukemia in western countries. Recent therapeutic advances have improved the rate and duration of remission, although there is no consensus over the optimum regimen.  CML has a lower incidence than CLL, but is a... <br/><font color="red">Category:  Editor's Choice Reports</font><br/><font color="blue">Published: 24-Nov-08</font><br/><font color="teal">Pages: 362</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Stakeholder Insight: Infertility - Undifferentiated drugs force need to strengthen prescriber and payer relationship]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2813</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Over 11.5 million women suffer from infertility in the seven major markets. Although prevalence rates are stable, the trend towards later parenthood is inducing an increasing demand for infertility treatments. As cost of therapy is the major ... <br/><font color="red">Category:  Editor's Choice Reports</font><br/><font color="blue">Published: 17-Dec-08</font><br/><font color="teal">Pages: 189</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Stakeholder Insight: Spondyloarthropathies - Disease perception limits market potential]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2800</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Psoriatic arthritis and ankylosing spondylitis form part of the group of diseases known as the spondyloarthropathies. Psoriatic arthritis is a form of inflammatory arthritis associated with psoriasis, whilst ankylosing spondylitis causes arth... <br/><font color="red">Category:  Editor's Choice Reports</font><br/><font color="blue">Published: 23-Dec-08</font><br/><font color="teal">Pages: 195</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Stakeholder Insight: Systemic Lupus Erythematosus  Imprecise segmentation complicates treatment algorithms]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2779</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Lupus is a chronic, autoimmune disorder, characterized by unpredictable flares and remissions. Affected areas can include the joints, skin, kidneys, heart, lungs, blood vessels and the brain. There are currently only three medications approve... <br/><font color="red">Category:  Editor's Choice Reports</font><br/><font color="blue">Published: 18-Nov-08</font><br/><font color="teal">Pages: 179</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Stakeholder Opinions: Bladder Cancer - New drugs needed to challenge ineffective 20-year old drugs]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2780</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

The overall incidence of bladder cancer in the seven major markets is forecast to exceed 160,000 by the end of 2008. Treatment of bladder cancer employs mainly immunotherapy and chemotherapy. However, both these methods are ineffective in imp... <br/><font color="red">Category:  Editor's Choice Reports</font><br/><font color="blue">Published: 12-Nov-08</font><br/><font color="teal">Pages: 95</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Stakeholder Opinions: Diabetic Renal Disease]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2783</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Prevalence of diabetic renal disease is on the rise. Current treatment focuses on the management of hypertension and glycemic control, but is unable to address the deterioration of renal function. An unmet need exists for therapies fully reve... <br/><font color="red">Category:  Editor's Choice Reports</font><br/><font color="blue">Published: 5-Nov-08</font><br/><font color="teal">Pages: 88</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Stakeholder Opinions: Narcolepsy - Entry-point to a lucrative fatigue-associated market]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2811</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Narcolepsy is a chronic sleep disorder, which affects fewer than 500,000 sufferers across the seven major markets (7MM). The narcolepsy market value has grown considerably since 2004 to reach $230m in 2007 driven largely by the significant pe... <br/><font color="red">Category:  Editor's Choice Reports</font><br/><font color="blue">Published: 18-Dec-08</font><br/><font color="teal">Pages: 105</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Stakeholder Opinions: Restless Legs Syndrome - Novel drugs to prosper as lifecycle management strategies fail]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2778</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Restless legs syndrome (RLS) is a neurological condition, which affects 15.5 million medically significant sufferers across the seven major markets (7MM). Through Requip (ropinirole) and Mirapex's (pramipexole) regulatory approvals in 200506,... <br/><font color="red">Category:  Editor's Choice Reports</font><br/><font color="blue">Published: 19-Nov-08</font><br/><font color="teal">Pages: 125</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Stakeholder Opinions: Sarcomas]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2797</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Sarcomas are a diverse group of rare connective tissue tumors that are  categorized as soft tissue sarcomas or bone sarcomas. Although sarcomas represent only 1% of all adult and 15% of all childhood cancers, the development of metastatic dis... <br/><font color="red">Category:  Editor's Choice Reports</font><br/><font color="blue">Published: 25-Dec-08</font><br/><font color="teal">Pages: 108</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Stakeholder Opinions: Type 2 Diabetes in the UAE & Saudi Arabia  Growth opportunities in fragmented markets]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2805</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This report focuses on the challenges of diverse and uncoordinated treatment paradigms for diabetes and the movement to rationalize efforts and establish best practice. Datamonitor uncovers the unique dynamics of the two largest diabetes mark... <br/><font color="red">Category:  Editor's Choice Reports</font><br/><font color="blue">Published: 19-Dec-08</font><br/><font color="teal">Pages: 115</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[The Cancer Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2764</link>
			<author><![CDATA[Source: Business Insights]]></author>
		 <description><![CDATA[The Cancer Market Outlook to 2013
Competitive landscape, pipeline analysis and growth opportunities
The market for cancer treatments is one of the largest and fastest growing areas in the pharma industry. Most innovation in oncology over the past 10 years ... <br/><font color="red">Category:  Editor's Choice Reports</font><br/><font color="blue">Published: Dec-08</font><br/><font color="teal">Pages: 128</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[The Pharmaceutical Market Outlook to 2018: Key threats and opportunities for Big Pharma and its responses to them]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2765</link>
			<author><![CDATA[Source: Business Insights]]></author>
		 <description><![CDATA[The Pharmaceutical Market Outlook to 2018
Key threats and opportunities for Big Pharma and its responses to them

The Pharmaceutical Market Outlook to 2018

The pharmaceutical industry must respond to a number of key challenges over the next ten years in o... <br/><font color="red">Category:  Editor's Choice Reports</font><br/><font color="blue">Published: Nov-08</font><br/><font color="teal">Pages: 158</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[The Top Ten Specialty Pharmaceutical Companies: Positioning, performance and SWOT analyses]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2766</link>
			<author><![CDATA[Source: Business Insights]]></author>
		 <description><![CDATA[The Top Ten Specialty Pharmaceutical Companies
Positioning, performance and SWOT analyses

Specialty pharmaceutical companies focus the majority of their efforts upon one or two therapeutic areas that are served by specialized physicians. Their traditional... <br/><font color="red">Category:  Editor's Choice Reports</font><br/><font color="blue">Published: Nov-08</font><br/><font color="teal">Pages: 189</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Forecast Insight: Asthma/COPD - Little long-term future for long-acting single-agent inhalers?]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2756</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

The respiratory market will continue to grow with the same rate over the next few years, with a slight dip between 2012 and 2015 due to the patent expiries of leading products. Growth is driven by the expansion of sales in existing classes,... <br/><font color="red">Category: Allergy & Respiratory</font><br/><font color="blue">Published: 7-Aug-08</font><br/><font color="teal">Pages: 125</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Forecast Insight: Multiple Sclerosis - Tysabri to prevail despite safety setbacks]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2749</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Overview

Introduction
Spurred by uptake of Biogen Idec and Elan's Tysabri (natalizumab) and continued revenue growth for the three beta-interferon brands and Teva's Copaxone (glatiramer acetate), the seven major multiple sclerosis market value increase... <br/><font color="red">Category: Neurology</font><br/><font color="blue">Published: 20-Aug-08</font><br/><font color="teal">Pages: 127</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Commercial Insight: Top 20 Therapy Cancer Brands - Key brands set to consolidate advantage as competition intensifies]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2748</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Overview

Introduction
Cancer therapy brand sales totaled over $30 billion in the seven major markets in 2007, growing by 20.1% since 2006. The high growth of this market makes it attractive to companies keen to emulate the blockbuster status achieved b... <br/><font color="red">Category: Oncology</font><br/><font color="blue">Published: 21-Aug-08</font><br/><font color="teal">Pages: 401</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Commercial Insight: Antihormonal Therapy Cancer Brands - Careful lifecycle management needed to preserve brand dominance]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2747</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Overview

Introduction
Antihormonal therapies are a class of cancer therapeutics that generated branded drug sales of $5.8 billion in the seven major pharmaceutical markets in 2007. However, the relative maturity of the market means that it is has becom... <br/><font color="red">Category: Oncology</font><br/><font color="blue">Published: 21-Aug-08</font><br/><font color="teal">Pages: 183</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Forecast Insight: Insomnia  Orexin and serotonin receptor modulators to innovate market]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2746</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

After 3 years of steady growth, the value of the insomnia market across the seven major markets (7MM) slumped by 12% to $4.1 billion in 2007 due to rapid generic erosion of Sanofi-Aventis's market leader Ambien (zolpidem) in the US. However... <br/><font color="red">Category: Insomnia</font><br/><font color="blue">Published: 20-Aug-08</font><br/><font color="teal">Pages: 148</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Commercial Insight: HIV - The battle for market share is getting fiercer]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2745</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

In 2007, HIV drugs achieved sales of $9.3 billion in the 7MM, growing faster than the overall market at a CAGR of 11.3% from 2004-2007. Due to patent expirations, Datamonitor expects the market's growth to slow down somewhat, reaching total... <br/><font color="red">Category: HIV/AIDS</font><br/><font color="blue">Published: 20-Aug-08</font><br/><font color="teal">Pages: 188</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Commercial Insight: Select herpes viruses and human papilloma virus - Non-biologic interventions for oral and genital herpes, cytomegalovirus infection, herpes zoster and genital warts]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2743</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Despite high unmet need, the market for the small molecules used to manage conditions such as genital and oral herpes, genital warts, cytomegalovirus retinitis and pneumonia or shingles has been neglected compared with the successfully prom... <br/><font color="red">Category: Antivirals</font><br/><font color="blue">Published: 26-Aug-08</font><br/><font color="teal">Pages: 270</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Forecast Insight: Dyslipidemia - Genericization and negative trial data drive market shrinking]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2742</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

The antidyslipidemic market is expected to fall to $20 billion in 2017. The decline will be driven by the deep genericization of the market, further exacerbated by the patent expiries of the top antidyslipidemic, Pfizer's Lipitor, as well a... <br/><font color="red">Category: Cardiology</font><br/><font color="blue">Published: 27-Aug-08</font><br/><font color="teal">Pages: 80</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Forecast Insight: Antidiabetics - Switching to new molecule antidiabetics drives market growth]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2741</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Datamonitor expects the antidiabetics market to reach $29 billion, across the seven major markets, by 2017. The growth will be driven by the launch of new drug classes, notably the DPP-IV inhibitors and GLP-1 agonists, and large growth in p... <br/><font color="red">Category: Endocrinology</font><br/><font color="blue">Published: 26-Aug-08</font><br/><font color="teal">Pages: 74</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Commercial Insight: Inflammatory Bowel Disease - Convenience and compliance drive market success]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2740</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Several product launches and indication expansion caused substantial sales growth in the seven major inflammatory bowel disease markets from $1.7 billion in 2004 to $2.7 billion in 2007. Datamonitor forecasts the IBD market will grow with a... <br/><font color="red">Category: Gastroenterology</font><br/><font color="blue">Published: 8-Sep-08</font><br/><font color="teal">Pages: 263</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Forecast Insight: Parkinson's Disease - Market upgrade following evidence of disease slowing with Azilect]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2739</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Stimulated by evidence of disease slowing with Teva/Lundbeck's Azilect (rasagiline), and successful reformulation of leading dopamine agonists, the Parkinson's disease market value is set to grow by an compound annual growth rate (CAGR) of ... <br/><font color="red">Category: Neurology</font><br/><font color="blue">Published: 8-Sep-08</font><br/><font color="teal">Pages: 123</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor types]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2735</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

In 2008, the six tumor types covered in this report are forecast to account for over 1.2m new cases of cancer. Collectively, the 36 different drugs in Phase III development for the six tumor types are forecast to achieve $7,049m in sales by... <br/><font color="red">Category: Oncology</font><br/><font color="blue">Published: 25-Sep-08</font><br/><font color="teal">Pages: 287</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Trends in Clinical Trials: Strategies to enhance clinical trial design]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2734</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Pharma is experiencing tough times, facing both economic and regulatory pressures, with increasing demands for improved safety data and comparative efficacy studies. Consequently, the duration, size, complexity and ultimately cost of clinic... <br/><font color="red">Category: Clinical Trials</font><br/><font color="blue">Published: 25-Sep-08</font><br/><font color="teal">Pages: 110</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Trends in Pharmaceutical Portfolio Management - Strategies to maintain profitability despite adversity]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2733</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

With growing competition, Pharma companies are under increased pressure to deliver additional value for key stakeholders through their portfolios. Companies with comprehensive portfolios offering more to physicians, patients, payers and pha... <br/><font color="red">Category: Pharma Portfolio</font><br/><font color="blue">Published: 25-Sep-08</font><br/><font color="teal">Pages: 108</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[The Anti-Infectives Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2728</link>
			<author><![CDATA[Source: Business Insights]]></author>
		 <description><![CDATA[The Anti-Infectives Market Outlook to 2013
The market for anti-infectives related disorders is set to become increasingly challenging as growing numbers of infectious pathogens become resistant to existing therapies. The resultant shift in R&D strategies ... <br/><font color="red">Category: Antibiotics</font><br/><font color="blue">Published: Aug-08</font><br/><font color="teal">Pages: 212</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Innovations and Pipelines for Respiratory Disorders: Niche markets, new products and future developments]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2727</link>
			<author><![CDATA[Source: Business Insights]]></author>
		 <description><![CDATA[Innovations and Pipelines for Respiratory Disorders
Niche markets, new products and future developments

Business Intelligence for the Pharmaceutical Industry
Business Insights' portfolio of healthcare management reports is designed to help you make we... <br/><font color="red">Category: Pharma Pipeline</font><br/><font color="blue">Published: Aug-08</font><br/><font color="teal">Pages: 145</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Innovative Strategies and Models for R&D Success: The evolving networked pharma company]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2726</link>
			<author><![CDATA[Source: Business Insights]]></author>
		 <description><![CDATA[Innovative Strategies and Models for R&D Success
The evolving networked pharma company

Report overview
Many pharma companies are currently engaged in wide-scale R&D restructuring, adopting a biotechnological approach to drug development by establishin... <br/><font color="red">Category: Drug Development</font><br/><font color="blue">Published: Aug-08</font><br/><font color="teal">Pages: 196</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[The Future of RNAi Therapeutics: Drug Pipelines and Prospects]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2725</link>
			<author><![CDATA[Source: Business Insights]]></author>
		 <description><![CDATA[The Future of RNAi Therapeutics: Drug pipelines and prospects
 
&quot;The total RNAi therapy market is estimated to value $580m by 2012. This forecast is based upon current treatments, levels of market satisfaction and five new Phase II/III RNAi agents p... <br/><font color="red">Category: RNAi Therapeutics</font><br/><font color="blue">Published: Sep-08</font><br/><font color="teal">Pages: 253</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[The CNS Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2724</link>
			<author><![CDATA[Source: Business Insights]]></author>
		 <description><![CDATA[The CNS Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
  
&quot;The global CNS disorders market expanded by 8.0% from 2006, to reach total sales of $77.3bn in 2007. This growth has been primarily driven by treat... <br/><font color="red">Category: Neurology</font><br/><font color="blue">Published: Sep-08</font><br/><font color="teal">Pages: 231</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Successful Pharmabiotech Alliance Strategies: Driving synergies, avoiding failure and managing relationships]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2723</link>
			<author><![CDATA[Source: Business Insights]]></author>
		 <description><![CDATA[Successful Pharma-Biotech Alliance Strategies
Driving synergies, avoiding failure  and managing relationships
&quot;The average value of pharma-biotech deals will almost treble by 2015 as pharma companies focus on gaining exclusive access to high potenti... <br/><font color="red">Category: Pharma-Biotech Alliances</font><br/><font color="blue">Published: Sep-08</font><br/><font color="teal">Pages: 143</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[MGI Pharm: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2437</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

MGI Pharma’s main focus is to develop and commercialize products for the treatment of diseases in the areas of oncology and acute care. The company has five marketed products, namely Aloxi, Dacogen, Gliadel Wafer, Salagen and Hexalen.

Sc... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 02-Nov-07</font><br/><font color="teal">Pages: 56</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Genentech Inc.: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2755</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for Genentech in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 7-Aug-08</font><br/><font color="teal">Pages: 131</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Chugai Pharmaceutical Co. Ltd: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2754</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for Chugai in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, w... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 7-Aug-08</font><br/><font color="teal">Pages: 156</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Boehringer Ingelheim GmbH: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2753</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for Boehringer Ingelheim in the Rx pharmaceutical sector. The profile encompasses  company strategy, portfolio and pipeline analysis and assessment of financial performance, wit... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 7-Aug-08</font><br/><font color="teal">Pages: 106</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Abbott Laboratories: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2752</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for Abbott in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, w... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 7-Aug-08</font><br/><font color="teal">Pages: 163</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Eli Lilly & Co.: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2751</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for Eli Lilly in the Rx pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 7-Aug-08</font><br/><font color="teal">Pages: 117</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[GlaxoSmithKline plc: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2750</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for GSK in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 ... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 7-Aug-08</font><br/><font color="teal">Pages: 139</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[UCB S.A.: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2737</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for UCB in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 8-Sep-08</font><br/><font color="teal">Pages: 149</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Celgene Corporation: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2736</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for Celgene in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, ... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 16-Sep-08</font><br/><font color="teal">Pages: 133</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Genzyme Corporation: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2732</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for Genzyme in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, ... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 23-Sep-08</font><br/><font color="teal">Pages: 145</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Alcon Inc.: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2731</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for Alcon in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, wi... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 23-Sep-08</font><br/><font color="teal">Pages: 118</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Nycomed A/S: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2730</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for Nycomed in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, ... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 23-Sep-08</font><br/><font color="teal">Pages: 114</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Pfizer Inc.: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2675</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for Pfizer in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 28-Jul-08</font><br/><font color="teal">Pages: 189</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Bristol-Myers Squibb Co.: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2680</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for BMS in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 ... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 16-Jul-08</font><br/><font color="teal">Pages: 157</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Novo Nordisk A/S: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2681</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for Novo Nordisk in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, ... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 16-Jul-08</font><br/><font color="teal">Pages: 139</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Amgen Inc.: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2682</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for Amgen in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 15-Jul-08</font><br/><font color="teal">Pages: 146</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Schering-Plough Corporation: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2686</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for Schering-Plough in the ethical pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with ... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 2-Jul-08</font><br/><font color="teal">Pages: 164</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[AstraZeneca plc: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2690</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for AstraZeneca in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, w... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 1-Jul-08</font><br/><font color="teal">Pages: 174</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Wyeth: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2692</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for Wyeth in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, wi... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 1-Jul-08</font><br/><font color="teal">Pages: 158</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Bayer Schering Pharma AG: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2693</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for Bayer Schering Pharma in the ethical pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance,... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 1-Jul-08</font><br/><font color="teal">Pages: 183</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[PharmaVitae: Company Comparator Tool]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2696</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

The Comparator Tool builds from the PharmaVitae profiles of the 50 leading pharma companies. Updated monthly, the tool allows you to compare the 50 players by current and forecast sales to 2012.

Reasons to Purchase

*Compare players by... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 25-Jun-08</font><br/><font color="teal">Pages: 0</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Poniard Pharmaceuticals Inc: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2608</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Poniard Pharmaceuticals, formerly known as NeoRx Corporation, is a biopharmaceutical company focused on the discovery, development and commercialization of cancer therapy products. The company’s lead product candidate, Picoplatin, is curren... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 41</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Theratechnologies Inc: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2607</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Theratechnologies is a Canadian biopharmaceutical company developing therapeutic peptides for endocrine and metabolic disorders. The company has developed its product pipeline utilizing two technologies ExoPep and LAP (Long Acting Peptide).... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 45</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Introgen Therapeutics Inc: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2606</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Introgen Therapeutics (Introgen) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer. The company has been successful in developing a strong ... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 53</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Lev Pharmaceuticals Inc: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2605</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Lev Pharmaceuticals is a development stage biopharmaceutical company engaged in developing and commercializing therapeutics based on C1-esterase inhibitor (C1-INH) for the treatment of inflammatory diseases. Cinryze, the company’s lead drug... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 34</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[MorphoSys AG: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2604</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

MorphoSys is a biotechnology company focused on the research and development of antibody drugs. The company’s main technology platform includes HuCAL (Human Combinatorial Antibody Library), an innovative technology which allows rapid and au... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 45</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Cougar Biotechnology Inc: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2603</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Cougar Biotechnology is a development stage biopharmaceutical company engaged in acquiring and developing products for the treatment of cancer. The company has built its development portfolio through in-licensing product candidate strategy.... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 39</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Cytori Therapeutics Inc: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2602</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Cytori Therapeutics (previously MacroPore Biosurgery), based in San Diego, California, is one of the leading companies in the development and commercialization of regenerative medicine products.

Scope

Contains corporate strategy, valu... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 45</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[MannKind Corporation: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2601</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

MannKind, a development-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic products for metabolical disorder and cancer. Technosphere Insulin (TI) System is the company's lead product candidate ... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 46</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Illumina Inc: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2599</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Illumina is one of the leading companies in genome and genotyping market. The company’s proprietary technology enables conversion of raw sequence data from the human genome into medically relevant information. The January 2007 acquisition o... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 46</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[LifeCell Corporation: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2600</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

LifeCell Corporation (LifeCell) develops, processes and markets biologically-based products in the emerging field of regenerative medicine. The company's proprietary human tissue matrix has been successfully used in more than 1 million graf... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 46</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Novacea Inc: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2598</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Novacea is a development stage biopharmaceutical company engaged in in-licensing, developing and commercializing of novel therapies for the treatment of diseases in the therapeutic area of oncology. The company’s lead candidate, Ascenter, i... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 39</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[St. Jude Medical Inc: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2597</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

SJM develops, manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management, cardiac surgery, cardiology, and atrial fibrillation therapy areas and implantable neuromodulation devices. The company has ... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 59</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[TorreyPines Therapeutics Inc: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2596</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

TorreyPines Therapeutics is a San-Diego-based biotechnology company formed through a reverse-merger with publicly-held Axonyx in October 2006. Previously known as Neurogenetics, TorreyPines is focused on the discovery and development of nov... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 47</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Transition Therapeutics Inc: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2595</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Transition Therapeutics is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. The company’s patented drug discovery technologies have helped the company in expanding its pipeline portfolio... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 46</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Smith & Nephew plc: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2594</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Smith & Nephew is a diversified medical technology group specializing in orthopaedic reconstruction, orthopaedic trauma and clinical therapies, endoscopy and advanced wound management products. The group acquired two companies, Plus Orthope... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 67</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Medtronic Inc: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2593</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Medtronic is a diversified medical technology company engaged in manufacturing a range of medical devices and therapies for the treatment of heart and vascular disease, neurological disorders, chronic pain, spinal disorders, diabetes, urolo... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 68</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Danaher Corporation: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2592</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Danaher is a diversified technology company engaged in designing, manufacturing and marketing of professional, medical, industrial and consumer products with strong brand names and significant market positions.

Scope

Contains corporat... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 48</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[C.R. Bard Inc: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2591</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

C.R. Bard (Bard), which celebrated its centenary in 2007, is one of the leading global developer, manufacturer and marketer of medical technologies in the fields of vascular, urology, oncology and surgical specialty products. The company ha... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 57</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Avigen Inc: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2590</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Avigen is a development stage biopharmaceutical company focusing on small molecule therapeutics and biologics to treat neurological and neuromuscular disorders. The company’s current pipeline products primarily address spasticity and neurom... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 39</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[KV Pharmaceutical Company: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2589</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

KV Pharmaceutical is a fully integrated specialty pharmaceutical company that develops, manufactures, markets and acquires technology-distinguished branded and generic/non-branded prescription pharmaceutical products. The company received t... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 61</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Lexicon Pharmaceuticals Inc: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2588</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Lexicon Pharmaceuticals is a biopharmaceutical company focused on clinical development in the areas of irritable bowel syndrome, cognitive disorders, autoimmune diseases, and carcinoid syndrome. The company uses its proprietary gene knockou... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 51</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[La Jolla Pharmaceutical Co: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2587</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

La Jolla Pharmaceutical (La Jolla) is a development stage biotechnology company focused entirely on novel antibody therapies for specific autoimmune diseases. The company’s only clinical stage candidate, Riquent, is being studied in Phase I... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 38</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Panacos Pharmaceuticals Inc: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2586</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Panacos Pharmaceuticals is a development stage biotechnology company specialized in developing antiviral products for the treatment of patients with HIV infection. The company’s lead drug candidate, bevirimat (formerly PA-457) is an HIV mat... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 44</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Stryker Corporation: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2585</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Stryker Corporation (Stryker) develops, manufactures and markets medical devices and instrumentations in the orthopedic as well the other medical surgical markets. While it is best known for its orthopedic products, it also has a material p... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 59</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Spectrum Pharmaceuticals Inc: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2582</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Spectrum Pharmaceuticals (Spectrum) is a biopharmaceutical company with a diversified portfolio of generic products and a pipeline of proprietary and collaborative products. Its therapeutic focus is on various cancer indications, infections... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 46</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Javelin Pharmaceuticals Inc: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2581</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Javelin Pharmaceuticals is a late development stage specialty pharmaceutical company that discovers, develops and commercializes drugs and improved formulations of existing drugs that target pain management market.

Scope

Contains corp... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 48</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Optimer Pharmaceuticals Inc: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2580</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Optimer is a biopharmaceutical company focused on the discovery, development and global commercialization of anti-infective products for the treatment of serious infectious diseases. The Company currently has two late stage anti-infective p... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 40</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[CSL Limited: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2578</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

CSL is a global, specialty biopharmaceutical company engaged in the research, development, manufacture and marketing of pharmaceutical products of biological origin such as vaccines and plasma protein biotherapies. It operates globally thro... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 74</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Varian Medical Systems Inc: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2577</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Varian Medical Systems (Varian) is one of the leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy and brachytherapy. The company is also a sup... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 56</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Zimmer Holdings Inc: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2576</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Founded in 1927, Zimmer Holdings is a diversified international orthopedic company with share leadership in multiple product categories including the $10 billion hip and knee replacement market.

Scope

Contains corporate strategy, valu... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 56</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Carl Zeiss Meditec AG: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2575</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Carl Zeiss Meditec is an integrated medical technology company that develops, manufactures and markets diagnostic and therapeutic systems for the treatment of vision defects, cataracts, glaucoma and retinal disorders. The company operates i... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 42</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Boston Scientific Corporation: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2574</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Boston Scientific is one of the leading companies in less-invasive medical devices market offering more than 15,000 products in over 45 countries across the world under the four core business groups: cardiovascular, endosurgery, neuromodula... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 67</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Anesiva Inc: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2573</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Anesiva (previously Corgentech), based in South San Francisco, California, is a late stage biotechnology company with two product candidates: Zingo and Altea for the potential treatment of various pain management indications. The company me... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 49</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[BIOMS Medical Corp: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2572</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two ... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 35</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Beckman Coulter Inc: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2571</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Beckman Coulter is a manufacturer of medical devices and diagnostic kits used to conduct basic research for developing vaccines and drugs to treat diseases, to conduct preclinical and clinical development, and to perform simple patient bloo... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 56</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Biotechnology: Global Industry Guide]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=1666</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Datamonitor's Biotechnology: Global Industry Guide is an essential resource for top-level data and analysis covering the biotechnology industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive l... <br/><font color="red">Category: General</font><br/><font color="blue">Published: 4-Dec-06</font><br/><font color="teal">Pages: 174</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[The Future of Monoclonal Antibodies Therapeutics: Innovation in antibody engineering, key growth strategies and forecasts to 2011]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=1520</link>
			<author><![CDATA[Source: Business Insights]]></author>
		 <description><![CDATA[The monoclonal antibody (mAb) market has grown rapidly in recent years, reaching sales of $14bn in 2005, an increase of 36.5% from 2004 sales of $10.3bn. K&ouml;hler and Milstein developed the hybridoma method of murine antibody production in 1975, which a... <br/><font color="red">Category: Monoclonal Antibodies</font><br/><font color="blue">Published: Jul-06</font><br/><font color="teal">Pages: 180</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[F. Hoffmann-La Roche Ltd.: PharmaVitae Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2729</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

This analysis examines the historical and forecast performance for Roche in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, wi... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 23-Sep-08</font><br/><font color="teal">Pages: 193</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Antisoma plc: Premium Company Profile]]></title>
			<link>http://salesandmarketingnetwork.com/reports.php?ID=2570</link>
			<author><![CDATA[Source: Datamonitor]]></author>
		 <description><![CDATA[Introduction

Antisoma is a development stage biotechnology company focused on the development of novel anticancer drugs. The Company has built a diversified product pipeline based on in-licensing and acquisitions that target a variety of tumors by diffe... <br/><font color="red">Category: Company Profiles</font><br/><font color="blue">Published: 22-Apr-08</font><br/><font color="teal">Pages: 42</font>]]>
			</description>
	</item>
	</channel>
</rss>